University of Michigan

K-12 Game-based Learning Market size to grow by USD 16.50 billion from 2022 to 2027, the market is fragmented due to the presence of prominent companies like Alphabet Inc., Banzai Labs Inc. and BrainQuake Inc., and many more - Technavio

Retrieved on: 
Monday, January 8, 2024
Knowledge, Online, Kuato Studios, KILLER, Special education, Student, Sustainability, Curriculum, Environment, Learning management system, USD, Geography, Parental Control, Learning analytics, Movement, Filament, Minecraft, Artificial intelligence, Augmented reality, University, Filament Games, IPad, Video, LMS, Teacher education, Breakaway, VR, M-learning, Coding, BYOD, Virtual reality, Learning, Social studies, Google Classroom, Tablet, Alphabet Inc., History, Interactivity, Computer architecture simulator, Educational technology, Social, University of Michigan, K-12, Growth, Microsoft, STEM, Video game

The K-12 game-based learning market is fragmented owing to the presence of many global and regional companies.

Key Points: 
  • The K-12 game-based learning market is fragmented owing to the presence of many global and regional companies.
  • Download a Free Sample before buying
    Alphabet Inc. - The company offers K-12 game-based learning solutions such as Google Classroom.
  • Banzai Labs Inc. - The company offers K-12 game-based learning solutions such as Banzai Classroom.
  • The K-12 Game-based Learning Market is witnessing substantial growth, driven by advancements in Virtual Learning Environments, Edutainment, and Learning Analytics.

Altair Announces Future.Industry 2024 Global Flagship Event

Retrieved on: 
Thursday, January 4, 2024
ALTR, Digital, Translation, Aptiv, Internet, AI, University, Internet of things, Science, HPC, University of Michigan, Artificial intelligence, Engineering, RapidMiner, Organization, Medical device

TROY, Mich., Jan. 4, 2024 /PRNewswire/ -- Altair (Nasdaq: ALTR), a global leader in computational science and artificial intelligence (AI) is pleased to announce Future.Industry 2024, the company's flagship annual event, which will take place virtually on March 6-7. The overarching theme is the "Science of Possibility," and will bring together thought leaders, industry experts, and visionaries to explore the trends and technologies poised to reshape tomorrow's world.

Key Points: 
  • Virtual event will explore the "Science of Possibility" and bring together thought leaders, industry experts, and visionaries to explore tomorrow
    TROY, Mich., Jan. 4, 2024 /PRNewswire/ -- Altair (Nasdaq: ALTR), a global leader in computational science and artificial intelligence (AI) is pleased to announce Future.Industry 2024 , the company's flagship annual event, which will take place virtually on March 6-7.
  • Future.Industry is a premier showcase of the latest and most powerful trends and technologies in today's market," said James R. Scapa, founder and chief executive officer, Altair.
  • "At this year's event, we will cover the latest advancements in computational science like few other events can."
  • To learn more about Future.Industry 2024 and to register for the event, visit https://events.altair.com/future-industry-2024/ .

Altair Announces Future.Industry 2024 Global Flagship Event

Retrieved on: 
Thursday, January 4, 2024
ALTR, Digital, Translation, Aptiv, Internet, AI, University, Internet of things, Science, HPC, University of Michigan, Artificial intelligence, Engineering, RapidMiner, Organization, Medical device

TROY, Mich., Jan. 4, 2024 /PRNewswire/ -- Altair (Nasdaq: ALTR), a global leader in computational science and artificial intelligence (AI) is pleased to announce Future.Industry 2024, the company's flagship annual event, which will take place virtually on March 6-7. The overarching theme is the "Science of Possibility," and will bring together thought leaders, industry experts, and visionaries to explore the trends and technologies poised to reshape tomorrow's world.

Key Points: 
  • Virtual event will explore the "Science of Possibility" and bring together thought leaders, industry experts, and visionaries to explore tomorrow
    TROY, Mich., Jan. 4, 2024 /PRNewswire/ -- Altair (Nasdaq: ALTR), a global leader in computational science and artificial intelligence (AI) is pleased to announce Future.Industry 2024 , the company's flagship annual event, which will take place virtually on March 6-7.
  • Future.Industry is a premier showcase of the latest and most powerful trends and technologies in today's market," said James R. Scapa, founder and chief executive officer, Altair.
  • "At this year's event, we will cover the latest advancements in computational science like few other events can."
  • To learn more about Future.Industry 2024 and to register for the event, visit https://events.altair.com/future-industry-2024/ .

AI is here – and everywhere: 3 AI researchers look to the challenges ahead in 2024

Retrieved on: 
Wednesday, January 3, 2024
Federal Trade Commission, Associate, Policy, Failure, Deception, Heel, Medicine, University, Student, School, Deep learning, University of Colorado Boulder, European, Information system, Life, Language, Ethicist, Congress, Education, ChatGPT, Disclosure, LLM, Technology, Information science, AI, Michigan State University, Fraud, Privacy, University of Michigan, Smartphone, FTC, Magic, Face, Social media, Human, YouTube, ELIZA, Information literacy, Time, Intelligence, Algorithm, Hearing, Medical device

The year saw the emergence of generative AI, which moved the technology from the shadows to center stage in the public imagination.

Key Points: 
  • The year saw the emergence of generative AI, which moved the technology from the shadows to center stage in the public imagination.
  • It also saw boardroom drama in an AI startup dominate the news cycle for several days.
  • We’ve assembled a panel of AI scholars to look ahead to 2024 and describe the issues AI developers, regulators and everyday people are likely to face, and to give their hopes and recommendations.
  • Casey Fiesler, Associate Professor of Information Science, University of Colorado Boulder 2023 was the year of AI hype.
  • One of the major AI debates of 2023 was around the role of ChatGPT and similar chatbots in education.
  • The more people understand how AI works, the more empowered they are to use it and to critique it.
  • I hope that universities that are rushing to hire more technical AI experts put just as much effort into hiring AI ethicists.


Anjana Susarla receives funding from the National Institute of Health and the Omura-Saxena Professorship in Responsible AI Casey Fiesler receives funding from the National Science Foundation, and is currently a funded Visiting Fellow with the Notre Dame-IBM Tech Ethics Lab. Kentaro Toyama's research is funded in part by the National Science Foundation.

Washtenaw Community College ahead of the curve with Esports arena, competitive teams

Retrieved on: 
Thursday, December 14, 2023
Transfer, Theta, Marketing, Java (programming language), WCC, Student, Eastern Michigan University, Phi, Industrial architecture, School, Animation, Entertainment management, University of Michigan, NACE, National Association, Student center, Communication, Sport, ANN, Washtenaw Community College, Washtenaw Technical Middle College, Super Smash Bros. Ultimate, Employment, Enrollment management, Technical, Video game

ANN ARBOR, Mich., Dec. 14, 2023 (GLOBE NEWSWIRE) -- As the Esports industry continues to grow, especially at the collegiate level, Washtenaw Community College (WCC) is ahead of the curve with its new Esports arena.

Key Points: 
  • ANN ARBOR, Mich., Dec. 14, 2023 (GLOBE NEWSWIRE) -- As the Esports industry continues to grow, especially at the collegiate level, Washtenaw Community College (WCC) is ahead of the curve with its new Esports arena.
  • Since the arena’s soft launch last spring, WCC’s Esports program has grown from two competitive teams, with the goal of soon adding a new all-women’s team.
  • Esports at WCC offers students a competitive advantage and positions them for success in the Esports industry and beyond.
  • Jay Howell, 19, of Ypsilanti, is dually enrolled as a WCC college student and a graduating Washtenaw Technical Middle College high school student.

BullFrog AI Launches Preclinical Study to Investigate BF-114’s Potential in Battling Obesity

Retrieved on: 
Wednesday, December 6, 2023
NAFLD, Risk, NASH, MOA, Non-alcoholic fatty liver disease, Small RNA, Michigan Medicine, Diabetes, Bullfrog, Obesity, University, Fatty liver disease, University of Michigan, DSM-IV codes, Artificial intelligence, Machine learning, SPTBN1, Medical device

GAITHERSBURG, Md., Dec. 06, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced the launch of a preclinical study to evaluate the efficacy of its drug candidate BF-114 in obesity. The study, which will be conducted in collaboration with Randy Seeley, Ph.D., the Henry King Ransom Endowed Professor of Surgery at Michigan Medicine, the academic medical center of University of Michigan, and Director of the Michigan Nutrition Obesity Research Center, is designed to evaluate the ability of BF-114 to modulate obesity in an established animal model and to elucidate the mechanism of action (MOA). The study is expected to be completed in the second quarter of 2024 and will complement internal activities that leverage the Company’s AI platform to identify and address new pathways for targeting obesity and metabolic diseases.

Key Points: 
  • The study is expected to be completed in the second quarter of 2024 and will complement internal activities that leverage the Company’s AI platform to identify and address new pathways for targeting obesity and metabolic diseases.
  • Obesity affects over 40% of the US population and is associated with increased risk of heart disease and diabetes.
  • Medical care costs for obesity-related health problems were estimated to be in excess of $170 billion in 2019.
  • “The market for obesity drugs is projected to exceed $77 billion by 2030 , and pharmaceutical companies around the world have recognized the importance of targeting multiple pathways to treat this condition,” said Vin Singh, CEO of BullFrog AI.

Math Ain't Mathing? Celebrate Kwanzaa with Automation Workz Vision Board App

Retrieved on: 
Thursday, December 28, 2023
Computer security, Invisibility, Hope, Book, FREE, Multimedia, Economy, Friends, Strayer University, African Americans, Responsibility, Noma (restaurant), Pessimism, Politics, Automation, Google Play, MBA, Apple, Creativity, AI, University, Internet of things, Jack Welch Management Institute, Purpose, Tech, Economic methodology, University of Michigan, Economics

Change that dynamic in 2024 with the Life Culture Audit vision board app.

Key Points: 
  • Change that dynamic in 2024 with the Life Culture Audit vision board app.
  • In 2023, my goal was to double the revenue of Automation Workz and finance my vision," exclaims Ida Byrd-Hill.
  • Ida created the Life Culture Audit vision board app to focus her learners on improving their lifestyle goals, daily.
  • Use the Life Culture Audit vision boarding app to create a pictorial vision of your desired income and lifestyle so the math adds up.

Harvard Apparatus Regenerative Technology Reports Third Quarter 2023 Financial Results

Retrieved on: 
Monday, November 13, 2023
Longevity, OTCQB, European Medicines Agency, University, Investment, University of Michigan, Clinical trial, EMA, IQVIA, Patient, Regenerative medicine, European, Clinical professor, E-commerce, Greater, LTD, Mayo Clinic, Pharmaceutical industry, Cryptocurrency, Hong Kong

Holliston, MA, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage biotechnology company developing the technology to regenerate organs inside the body to treat severe diseases, today announced its financial results for the three and nine months ended September 30, 2023.

Key Points: 
  • Holliston, MA, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage biotechnology company developing the technology to regenerate organs inside the body to treat severe diseases, today announced its financial results for the three and nine months ended September 30, 2023.
  • We activated the second clinical trial site with the University of Michigan in August 2023 to expand the screening of patients.
  • In the third quarter of 2023, the Company’s subsidiary in Hong Kong, Harvard Apparatus Regenerative Technology Limited, or HRGN LTD, launched its longevity product business in Asia, generating $40,000 in sales.
  • At September 30, 2023, the Company had operating cash and short-term investments on-hand as of $1.5 million.

Aquyre Biosciences Announces Appointment of Gregory Bowles as President and CEO

Retrieved on: 
Tuesday, December 5, 2023
Biotechnology, General Health, Health, Oncology, Granuloma, Senior, Intuitive Surgical, U.S. Navy Diving Manual, Pathology, National Security Agency, Lymphocyte, University of Michigan, Patient, Marketing, Capital, Lung cancer, Vincent van Gogh, Da Vinci Surgical System, University, Cancer, Diagnosis, DCI, Cell, State, Biopsy, Medical imaging

Aquyre Biosciences, Inc. today announced the appointment of Gregory Bowles as President, Chief Executive Officer and member of the Board of Directors.

Key Points: 
  • Aquyre Biosciences, Inc. today announced the appointment of Gregory Bowles as President, Chief Executive Officer and member of the Board of Directors.
  • At Intuitive Surgical during its early years, he was the Capital Sales Manager where he sold the daVinci Robot in Michigan.
  • Greg’s first startup was EndoGastric Solutions where he held positions as Regional Manager and later as Vice President of Sales.
  • While at Aquyre Biosciences, Greg was the Senior Vice President of Sales and Marketing and has been instrumental in building the company’s commercialization efforts.

Swing Therapeutics Announces Positive Results from Pivotal Phase 3 Trial of Stanza, a Digital Therapy for Fibromyalgia Symptoms

Retrieved on: 
Tuesday, November 14, 2023
Biotechnology, Technology, FDA, Health, General Health, Pharmaceutical, Health Technology, Medical Devices, Apps, Applications, Software, Clinical Trials, ACT, RCT, Fatigue, Fibromyalgia, Depression, De novo, Pivotal, Randomized controlled trial, Food, Commitment, Therapy, University of Michigan, CBT, Cognitive behavioral therapy, Patient, PROMIS, American College of Rheumatology, PGIC, American College, BDI, MD, Sleep, Phase 3, University, University of Cincinnati, FIQ, Doctor of Philosophy, Guideline, ACR, Chronic pain, PIPS, Pharmaceutical industry, Medical imaging, Medical device, Stanza, Swing

Swing Therapeutics, a leading developer of digital therapies for chronic pain conditions, today announced the successful completion of and positive results from its pivotal Phase 3 PROSPER-FM trial on Stanza, a self-guided smartphone-based behavioral therapy for the treatment of fibromyalgia symptoms in adult patients.

Key Points: 
  • Swing Therapeutics, a leading developer of digital therapies for chronic pain conditions, today announced the successful completion of and positive results from its pivotal Phase 3 PROSPER-FM trial on Stanza, a self-guided smartphone-based behavioral therapy for the treatment of fibromyalgia symptoms in adult patients.
  • Results from this multi-center, randomized controlled trial (RCT) were presented at the American College of Rheumatology (ACR) 2023 annual meeting this week.
  • Swing received De Novo marketing authorization from the U.S. Food and Drug Administration (FDA) for Stanza in May 2023, making it the first prescription digital therapeutic indicated for treating fibromyalgia symptoms.
  • It delivers acceptance and commitment therapy (ACT), a type of cognitive behavioral therapy (CBT) with proven efficacy in treating fibromyalgia and other chronic pain conditions.